Search
PMC-403
go.drugbank.com/drugs/DB18132InvestigationalPMC-403 is a novel Tie2-activating antibody being investigated for the treatment of systemic capillary leak syndrome.
Synonyms: a fully human monoclonal antibody that binds and activates the Tie2 receptorARGX-119
go.drugbank.com/drugs/DB18133InvestigationalARGX-119 is a monoclonal antibody that targets and activates muscle-specific kinase (MuSK).
Synonyms: a fully humanized immunoglobulin gamma 1 (IgG1) agonistic monoclonal antibody (mAb) that specifically targets and activates MuSKSGN-1
go.drugbank.com/drugs/DB18135InvestigationalSGN-1 is a genetically modified strain of _Salmonella enterica_ comprising methioninase.
Xaluritamig
go.drugbank.com/drugs/DB18137InvestigationalXaluritamig is a novel humanized bispecific T cell recruiting antibody cross-reactive to human and nonhuman primate STEAP1 and CD3.
SBT101
go.drugbank.com/drugs/DB18139InvestigationalSBT101 is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) gene therapy vector containing the human adenosine triphosphate (ATP)-binding cassette (ABC) sub-family D member 1 (ABCD1
Andusomeran
go.drugbank.com/drugs/DB18227ApprovedInvestigationalAndusomeran is a COVID-19 mRNA vaccine developed for use during the 2023-2024 season.[L40074,L48832,L48837] It is similar to previous mRNA vaccines developed by Moderna (e.g.
Opelconazole
go.drugbank.com/drugs/DB18251InvestigationalCategories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP3A Inducers